Leila Simani

Dr. Leila Simani


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2020 in Journal of the Neurological Sciences
Verified
Journal Article
Closed access
AAAli Asadi-Pooya
Ali Asadi-Pooya
LSLeila Simani
Leila Simani

11 June 2020 in ACS Chemical Neuroscience
Verified
Journal Article
Closed access
ATAbolfazl Torabi
Abolfazl Torabi
EMEsmaeil Mohammadbagheri
Esmaeil Mohammadbagheri
NDNader Akbari Dilmaghani
Nader Akbari Dilmaghani
ABAmir-Hossein Bayat
Amir-Hossein Bayat
MFMobina Fathi
Mobina Fathi
AAAbbas Aliaghaei
Abbas Aliaghaei

2 February 2021 in Journal of NeuroVirology
Verified
Journal Article
Open access
PDF file
LSLeila Simani
Leila Simani
MRMahtab Ramezani
Mahtab Ramezani
IDIlad Alavi Darazam
Ilad Alavi Darazam
MSMastooreh Sagharichi
Mastooreh Sagharichi
MAMohammad Amin Aalipour
Mohammad Amin Aalipour
HPHossein Pakdaman
Hossein Pakdaman
As the SARS-COV-2 becomes a global pandemic, many researchers have a concern about the long COVID-19 complications. Chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) is a persistent, debilitating, and unexplained fatigue disorder. We investigated psychological morbidities such as CFS and post-traumatic stress disorder (PTSD) among survivors of COVID-19 over 6 months. All COVID-19 survivors from the university-affiliated hospital of Tehran, Iran, were assessed 6 months after infection onset by a previously validated questionnaire based on the Fukuda guidelines for CFS/EM and DSM-5 Checklist for PTSD (The Post-traumatic Stress Disorder Checklist for DSM-5 or PCL-5) to determine the presence of stress disorder and chronic fatigue problems. A total of 120 patients were enrolled. The prevalence rate of fatigue symptoms was 17.5%. Twelve (10%) screened positive for chronic idiopathic fatigue (CIF), 6 (5%) for CFS-like with insufficient fatigue syndrome (CFSWIFS), and 3 (2.5%) for CFS. The mean total scores in PCL-5 were 9.27 ± 10.76 (range:0–44), and the prevalence rate of PTSD was 5.8%. There was no significant association after adjusting between CFS and PTSD, gender, comorbidities, and chloroquine phosphate administration. The obtained data revealed the prevalence of CFS among patients with COVID-19, which is almost similar to CFS prevalence in the general population. Moreover, PTSD in patients with COVID-19 is not associated with the increased risk of CFS. Our study suggested that medical institutions should pay attention to the psychological consequences of the COVID-19 outbreak.

8 June 2021 in ACS Chemical Neuroscience
Verified
Journal Article
Closed access
MBMahdi Eskandarian Boroujeni
Mahdi Eskandarian Boroujeni
LSLeila Simani
Leila Simani
HBHans A. R. Bluyssen
Hans A. R. Bluyssen
HSHamid Reza Samadikhah
Hamid Reza Samadikhah
SBSoheila Zamanlui Benisi
Soheila Zamanlui Benisi
AAAbbas Aliaghaei
Abbas Aliaghaei

30 July 2020 in Basic and Clinical Neuroscience Journal
Verified
Journal Article
Open access
PDF file
MRMahtab Ramezani
Mahtab Ramezani
LSLeila Simani
Leila Simani
EKEhsan Karimialavijeh
Ehsan Karimialavijeh
OROmidvar Rezaei
Omidvar Rezaei
MHMohammadreza Hajiesmaeili
Mohammadreza Hajiesmaeili
HPHossein Pakdaman
Hossein Pakdaman
Introduction: The outbreak due to Coronavirus Disease 2019 (COVID-19) is n global public health emergency and challenges psychological resilience. The central nervous system, endocrine system, and immune system are complex interacting systems. Cortisol has been implicated as the cause of a wide range of mental and physical health disorders; however, the impact ...

25 November 2020 in Neurological Sciences
Verified
Journal Article
Closed access
PDF file
AAAli Asadi-Pooya
Ali Asadi-Pooya
LSLeila Simani
Leila Simani
MSMina Shahisavandi
Mina Shahisavandi
ZBZohreh Barzegar
Zohreh Barzegar